This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Beta-CIT-SPECT and Neurophysiology in Depression

This study has been completed.
H. Lundbeck A/S
Information provided by:
Ludwig-Maximilians - University of Munich Identifier:
First received: September 1, 2005
Last updated: June 1, 2010
Last verified: May 2010
Aim of this project is to investigate the effects of escitalopram on monoamine transporter (SERT, DAT) availabilities as assessed by b-CIT and SPECT, and on neurophysiological parameters such as the loudness dependence of auditory evoked potentials (LDAEP) in patients with depression.

Condition Intervention Phase
Depression Procedure: β-CIT-SPECT, Neurophysiology Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Serotonin and Dopamine Transporter (SERT, DAT) Availabilities as Assessed by b-CIT and SPECT, and Neurophysiological Measures of Central Serotonergic Activity in Patients With Depression Under Treatment With Escitalopram

Resource links provided by NLM:

Further study details as provided by Ludwig-Maximilians - University of Munich:

Primary Outcome Measures:
  • changes in β-CIT/neurophysiological measurements from baseline to week 4 [ Time Frame: two assessments, at baseline and week 4 ]

Enrollment: 30
Study Start Date: June 2005
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: β-CIT-SPECT, Neurophysiology
    β-CIT-SPECT scans and EEG recordings, two assessments each

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Psychiatric in or outpatients with acute depressive episode
  • Indication for pharmacological treatment

Exclusion Criteria:

  • Acute suicidality
  • Neurological or severe somatic disorders
  • Occupational exposition to radiation >15 mSv per year
  • Women during pregnancy or lactation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00145132

Depts. of Psychiatry and Nuclear Medicine, Ludwig-Maximilians-University of Munich
Munich, Germany, D-80336
Sponsors and Collaborators
Ludwig-Maximilians - University of Munich
H. Lundbeck A/S
Principal Investigator: Oliver Pogarell, MD Dept. of Psychiatry, University of Munich
  More Information

Responsible Party: Oliver Pogarell, MD, University of Munich Identifier: NCT00145132     History of Changes
Other Study ID Numbers: ESCIT-SPECT-Pogarell
Study First Received: September 1, 2005
Last Updated: June 1, 2010

Keywords provided by Ludwig-Maximilians - University of Munich:

Additional relevant MeSH terms:
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs processed this record on September 21, 2017